Increasing evidence suggests that cancer cell pyroptosis can boost the host's antitumor immune activity, and when combined with immune checkpoint inhibitors, it has the potential to transform “cold tumors” into “hot tumors”, thereby exerting synergistic antitumor effects.[7] Here, our results showed that both single NIR‐pyroptosis therapy and combination therapy halted CT26.WT‐hICAM1/hHER2 tumor growth compared to the mock control group. The gene discussed is DDX53; the disease is cancer.